Skip to main content

Table 1 Patient baseline characteristics at time of sampling

From: Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma

Subject ID scRNA-seq FACS/RT-PCR Samples biopsied for scRNA-seq Age Sex Ethnicity Diagnosis Large cell transformation Disease duration (years) Ongoing treatment Previous treatments Disease stage
MF309 x x Patch and tumor (trunk) 76 Male Caucasian CD4+ MF, CD30+ Present Diagnosis 22 years ago; symptoms reported since age 37 ECP Topical GCS, IFN alpha IVA1 (T3N0M0B2)
MF309 x   Ulcerated tumor (follow-up lesion trunk) and nonlesional skin (trunk) 76    CD4+ MF, CD30+ Present   ECP Brentuximab IVA1 (T3N0M0B2)
MF311 x x Patch and plaque (trunk) 74 Female Caucasian CD4 + MF, CD30- Absent Diagnosis 2 years ago; symptoms reported since age 53 ECP NB-UVB, bexarotene, PUVA, topical and systemic GCS, IFN alpha, alemtuzumab, local radiotheraphy (x ray) IVA1 (T2N1M0B2)
MF311 x   Nonlesional skin (lower extremity) 74    CD4 + MF, CD30- Absent   ECP   IVA1 (T2N1M0B2)
MF311 x   Erythroderma (follow-up lesion upper extremity) 75    CD4 + MF, CD30- Absent   ECP, chlorambucil, systemic GCS   IVA1 (T4N1M0B2)
MF312 x   Patch and plaque (upper extremity) 55 Male Caucasian CD4 + MF, CD30+ Present Diagnosis 6 years ago; symptoms since age 44 ECP, IFN alpha, acitretin Topical GCS, NB-UVB, local radiotherapy (x ray) IIB* (T2bN0M0B0)
MF312 x   Cleared (follow-up) lesion (upper extremity) 56     n.a.   ECP, chlormethine   IIB* (T1aN0M0B0)
MF318 x   Patch and plaque (thigh) 55 Female Caucasian gamma/delta MF, CD30+ Absent Symptoms since age 52; recently diagnosed none Topical GCS and CNI, NB-UVB IIB** (T3N0M0B0)
P65 x   Patch and non-lesional skin (upper extremity) 53 Male Caucasian CD4 + MF, CD30- Absent Symptoms for > 10 years; recently diagnosed none Topical GCS IB (T2aN0M0B0)
P107 x   Patch lower back 39 Female Caucasian CD4−/CD8-MF, CD30+ Absent Symptoms for > 20 years; diagnosed at age 37 none Topical GCS IA (T1bN0M0B0)
P107   x Plaque lower back 39 Female Caucasian CD4−/CD8-MF, CD30+ Absent Symptoms for > 20 years; diagnosed at age 37 none Topical GCS IA (T1bN0M0B0)
P138 x   Patch thigh 47 Male Caucasian CD4 + MF Absent Symptoms for > 20 years; recently diagnosed none Topical GCS IA (T1aN0M0B0)
P73 x   Plaque and non-lesional skin (lower extremity) 82 Male Caucasian folliculotropic MF, CD30- Absent Diagnosis 6 years ago none PUVA, topical GCS, Re-PUVA, local radiotherapy IIB (T3N0M0B0)
P84 x   Plaque (upper extremity) 75 Male Caucasian CD4 + MF, CD30- Absent Symptoms for 6 months; recently diagnosed none NB-UVB, topical GCS IIB (T3N0M0B1)
P84 x   Cleared (follow-up) lesion (upper extremity) 75    CD4+ MF, CD30- Absent   PUVA   IIB (T3N0M0B1)
P90 x   Patch and non-lesional skin (upper extremity) 75 Male Caucasian CD4 + MF Absent Diagnosis at age 64 none topical GCS, PUVA, NB-UVB, bexarotene, acitretin IB (T2aN0M0B0)
P15   x Tumor trunk 59 Male Caucasian CD4 + MF, CD30+ Present Diagnosis at age 56 Brentuximab vedotin Topical and systemic GCS IIB (T3N0M0B0)
P182   x Patch and plaque (trunk) 49 Female Caucasian CD4 + CD8 + MF, CD30+ Absent Onset of symptoms 4 months ago, recently diagnosed none none IA (T1bN0M0B1)
P112 x   Healthy control skin 51 Female Caucasian n.a. n.a. n.a. none n.a. n.a.
P115 x   Healthy control skin 48 Male Caucasian n.a. n.a. n.a. none n.a. n.a.
P116 x   Healthy control skin 57 Female Caucasian n.a. n.a. n.a. none n.a. n.a.
P121 x   Healthy control skin 44 Female Caucasian n.a. n.a. n.a. none n.a. n.a.
  1. ECP Extracorporeal photopheresis, GCS glucocorticosteroids, IFN interferon, PUVA psoralen ultraviolet A photochemotherapy, NB-UVB narrow band ultraviolet B phototherapy, CNI calcineurin inhibitor, MF mycosis fungoides; *history of skin tumors successfully treated with local radiotherapy, ** tumor was not biopsied, only patch and plaque
Back to article page

Molecular Cancer

ISSN: 1476-4598